Compounder can’t shake US Lanham Act lawsuit by Novo Nordisk in Florida
False advertising and other claims by Novo Nordisk over compounded semaglutide aren't precluded by the Food, Drug and Cosmetic Act, a US judge ruled yesterday. Her decision draws an important distinction...To view the full article, register now.
Already a subscriber? Click here to view full article